谭大为,郑丹,陈秀萍
TAN Dawei,ZHENG Dan,CHEN Xiuping

• 1:贵州医科大学附属白云医院血液内科
• 2:贵阳护理职业学院
• 3:毕节市七星关区人民医院

摘要(Abstract)：

目的:探讨干扰素对人Burkitt's淋巴瘤细胞Raji增殖的影响及机制。方法:采用100、500、1 000、2 000及5 000 U/mL干扰素分别处理Raji细胞12、24及48 h,采用CCK-8法检测Raji细胞的增殖活性,实时荧光定量PCR扩增(QPCR)检测各浓度干扰素处理Raji细胞48 h时BZLFl、BRLFlmRNA表达水平。结果:各浓度干扰素对Raji细胞的增殖均有一定的抑制作用,且随着干扰素浓度的增加,其抑制作用逐渐增强,各浓度组间比较差异有统计学意义(P<0.05);各浓度干扰素均能上调Raji细胞BZLFl及BRLFlmRNA表达,且随着干扰素浓度增加,基因的表达量增多,各浓度组间比较差异有统计学意义(P<0.05)。结论:干扰素能抑制Raji细胞增殖、且呈浓度依赖性,其机制可能是通过上调BZLFl及BRLFl基因的表达来抑制Raji细胞的增殖。
Objective: To investigate the effect of interferon on the proliferation and expression of BZLFl mRNA, BRLFl mRNA in Raji cells and its mechanism.Methods: Raji cells were cultured and treated with 100, 500, 1 000, 2 000, 5 000 U/mL interferon for 12, 24, 48 h respectively.Then the cell proliferation was tested with CCK 8 assay. The expression of BZLFl and BRLFl mRNA in Raji cells treated with interferon at various concentrations for 48 h was detected by QPCR.Results: At the different concentrations of 100～5 000 U/mL, interferon effectively inhibited Raji cells proliferation and its inhibitory effect was gradually enhanced with the increase of interferon concentration, the difference between groups with different concentrations was statistically significant(P<0.05). All the selected interferon concentrations increased the expression of BZLFl mRNA, BRLFl mRNA in a dose-dependent manner. The expression of genes increased with the increasing of interferon concentration, and the difference between the groups with different concentrations was statistically significant(P<0.05). Conclusion: Interferon can inhibit proliferation by upregulating the expression of BZLFl mRNA and BRLFl mRNA in Raji cells.

关键词(KeyWords)： 淋巴瘤;EB病毒;Raji细胞;干扰素;增殖;抑制;BZLFl基因;BRLFl基因
lymphoma;EB virus;Raji cells;interferon;proliferation;inhibitation;BZLFl gene;BRLFl gene

Abstract:

Keywords:

基金项目(Foundation): 贵州省科学技术厅基金[黔科合LH字(2015)7398]

作者(Author): 谭大为,郑丹,陈秀萍
TAN Dawei,ZHENG Dan,CHEN Xiuping

DOI: 10.19367/j.cnki.1000-2707.2019.09.008

参考文献(References)：

• [1] 周静,肖毅.EB病毒与其相关淋巴瘤的研究进展[J].中国实验血液学杂志,2018,26(1):292-295.
• [2] 巴音,韩艳秋.EB病毒感染相关淋巴瘤的研究进展[J].临床血液学杂志,2018,31(2):240-244.
• [3] 郭丹,陈兵.EB病毒感染相关血液病发病机制的研究进展[J].临床血液学杂志,2018,31(2):231-235.
• [4] WU L,EHLIN-HENRIKSSON B,ZHOU X,et al.Epstein-Barr virus ( EBV ) provides survival factors to EBV+ diffuse large B-cell lymphoma ( DLBCL ) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL[J].Immunology,2017,152(4) :562-573.
• [5] CHEN Z H,LIU W P,ZHAO S.Systemic EBV-positive T-cell lymphoma of childhood mimicking anaplastic large cell lymphoma[J].British Journal of Haematology,2019,185(6):1016.
• [6] KAYMAZ Y,ODUOR CI,YU H,et al.Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences[J].Mol Cancer Res,2017,15(5):563-576.
• [7] CROMBIE J L,LACASCE A S.Epstein barr virus associated B-Cell lymphomas and iatrogenic lymphoproliferative disorders[J].Frontiers in Oncology,2019,9 :109.
• [8] 魏华萍.EB病毒感染对R-CHOP治疗弥漫大B细胞淋巴瘤影响的Meta分析[J].中国临床新医学,2018,11(9):884-888.
• [9] 魏天南,尚晋.初诊时EB病毒阳性淋巴瘤46例临床分析[J].中国现代医生,2018,56(33):87-90.
• [10]李海峰.干扰素治疗小儿EB病毒感染分子水平研究[J].吉林医学,2016,37(6):1370-1372.
• [11]戴欣,黄文祥.原发EB病毒感染诊治进展[J].现代临床医学,2015,41(2):103-106.
• [12]孙畅,路顺,郎锦义.EB病毒感染与鼻咽癌诊治的研究进展[J].肿瘤预防与治疗,2018,31(5):352-357.
• [13]赵凌丽.传染性单核细胞增多症异型淋巴细胞数量与EB病毒浓度的关系[J].中国医药指南,2019,17(11):153-154.
• [14]吴文蓉.EB病毒抗体检测对传染性单核细胞增多症的临床诊断意义[J].当代医学,2019,25(1):52-54.
• [15]曾艳,刘瑜.不同类型淋巴瘤患者的外周血EB病毒检测价值[J].中国当代医药,2019,26(8):81-83.
• [16]王巧合,胡鹏.29例成人EB病毒感染不同预后的临床特征分析比较[J].重庆医科大学学报,2017,42(7):803-807.
• [17]刘琳,高子芬,李敏,等.EB病毒阳性的胃弥漫大B细胞淋巴瘤特点及预后[J].中国肿瘤临床,2016,43(6):255-259.
• [18]刘文硕,南飞飞,贾思思,等.结外NK/T细胞淋巴瘤检测EB病毒与疗效关系的研究[J].中国肿瘤临床,2015,42(2):105-108.
• [19]叶云霞,张文燕,李甘地,等.中国西南地区老年人EB病毒阳性弥漫大B细胞淋巴瘤的临床病理特点及预后分析[J].四川大学学报(医学版),2014,45(4):652-657.
• [20]陈少红,叶子茵,杨静,等.EB病毒在老年性EBV阳性弥漫性大B细胞淋巴瘤中的潜伏感染类型[J].热带医学杂志,2016,16(6):725-727;748.
• [21]林建生,赖辉添,黄安清,等.间接免疫荧光方法研究EB病毒感染类型与免疫功能关系[J].当代医学,2019,25(14):26-28.
• [22]周志平,陈威巍,汤勃,等.EB病毒感染及其相关性疾病[J].传染病信息,2013,26(1):57-60.
• [23]李蒲,李源,肖承京,等.小白菊内酯对人淋巴瘤Raji细胞增殖的影响及机制探讨[J].世界最新医学信息文摘,2017,17(54):3-5.
• [24]李嵬,罗湘建,胡哲煜,等.EBV裂解复制周期调控机制研究新进展[J].病毒学报,2011,27(6):619-623.
• [25]唐凌.重组人干扰素α1b雾化治疗新生儿病毒性肺炎的疗效观察[J].检验医学与临床,2017,14(2):239-242.
• [26]张萍萍,刘钢.干扰素在中枢神经系统感染疾病中的应用研究进展[J].医学综述,2016,22(13):2530-2533.
• [27]王坤,朱传龙.干扰素治疗慢性乙型肝炎疗效预测因素的研究进展[J].临床与病理杂志,2015,35(6):1157-1163.
• [28]李海峰.干扰素治疗小儿EB病毒感染分子水平研究[J].吉林医学,2016,37(6):1370-1372.

文章评论(Comment)：